Strategic Evidence & Value Communication Symposium
Join us on Wednesday, April 21, 2021, from12:00 PM – 2:00 PM EDT for Certara’s…
CertaraMarch 26, 2021
Purity is a Virtue: A Practical Guide to the Reporting of Impurities
Many pharmaceutical companies struggle with characterizing drug substance (DS) and drug product (DP) impurities and…
CertaraMarch 23, 2021
IQ WG Evaluation of PBPK Models for Organ-Impaired Populations
• The predictive performance of physiologically based pharmacokinetic(s) (PBPK) models for PK in renal impairment…
CertaraMarch 10, 2021
Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors
It is crucial for biotech developers to engage in early commercial market assessment to generate…
CertaraMarch 5, 2021
Quantitative Systems Pharmacology for Drug Discovery and Development
Certara's Dr. Piet van der Graaf, Senior Vice President, Professor of Systems Pharmacology, Leiden University,…
CertaraMarch 2, 2021
RAPS Sponsored Webinar: Efficiency and Technology Pave the Way for the New Age of Narrative Writing
Narratives are an integral part of medical writing. Sponsors sometimes need to prepare large…
CertaraFebruary 8, 2021
How drug developers can avoid these common mistakes to secure a deal
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
CertaraJanuary 21, 2021
Making your biotech program investor-ready
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
CertaraJanuary 21, 2021
An Introduction to Asset Evaluation for Emerging Biotech Companies
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
CertaraJanuary 21, 2021
Mechanistic model-informed discovery & development of bispecific antibodies for immuno-oncology: It takes 2 to tango
More than 50 bispecific antibodies are in oncology clinical development with a large diversity in…
CertaraDecember 2, 2020
